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Abstract
Vasopressin (AVP) and oxytocin (OT) receptors (nomenclature as recommended by NC-IUPHAR [92]) are
activated by the endogenous cyclic nonapeptides vasopressin and oxytocin. These peptides are derived from
precursors which also produce neurophysins (neurophysin I for oxytocin; neurophysin II for vasopressin).
Vasopressin and oxytocin differ at only 2 amino acids (positions 3 and 8). There are metabolites of these
neuropeptides that may be biologically active [67].
Contents
This is a citation summary for Vasopressin and oxytocin receptors in the Guide to Pharmacology database
(GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and from the
database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the database
which are given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
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parts.
Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
version. If you need to consult the cited version, rather than the most recent version, please contact the GtoPdb
curators.
Database links
Vasopressin and oxytocin receptors
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=66
Introduction to Vasopressin and oxytocin receptors
http://www.guidetopharmacology.org/GRAC/FamilyIntroductionForward?familyId=66
    Receptors
            V1A receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=366
            V1B receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=367
            V2 receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=368
            OT receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=369
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